Hyperimmune Plasma in Patients With COVID-19 Severe Infection
Status:
Recruiting
Trial end date:
2021-05-15
Target enrollment:
Participant gender:
Summary
Passive immunotherapy through plasma infusion of convalescent subjects - convalescent plasma
- or "hyperimmune" plasma was one of the most widespread and effective anti-infective
treatments in the pre-antibiotic era and one of the founding pillars of immunology, and has
also been used during the SARS (2002-2003) and Ebola (2014-2016) viral epidemy for which
there were no alternative immunoprophylactic or therapeutic interventions.
To date, there are not proven etiological therapies for SARS-CoV-2 infection, the agent
responsible for the disease called Covid-19. Among those subjected to clinical studies during
the current epidemic in China, hyperimmune plasma appears to be one of the most rational and
promising.
The objective of this study will be to evaluate the efficacy and safety of the hyperimmune
plasma administered add-on to the anti-Covid-19 treatment (standard therapy) according to
clinical practice in patients with severe Covid-19 infection, compared to patients with
severe Covid-19 infection treated only with standard therapy.